ONE RESEARCH WAY, PRINCETON, NJ
Appoints Matt Eckler, Ph.D., to Board of Directors
Announces Pricing of Oversubscribed $50Million Public Offering of Securities
Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals Elects Directors at 2026 Annual Meeting
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Financial Results, Press Release
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
SC TO-I
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report